NO996205D0 - Behandling av insulinresistens med veksthormonutskillelsesmiddel - Google Patents

Behandling av insulinresistens med veksthormonutskillelsesmiddel

Info

Publication number
NO996205D0
NO996205D0 NO996205A NO996205A NO996205D0 NO 996205 D0 NO996205 D0 NO 996205D0 NO 996205 A NO996205 A NO 996205A NO 996205 A NO996205 A NO 996205A NO 996205 D0 NO996205 D0 NO 996205D0
Authority
NO
Norway
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretion
secretion
Prior art date
Application number
NO996205A
Other languages
English (en)
Other versions
NO996205L (no
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Treadway
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO996205D0 publication Critical patent/NO996205D0/no
Publication of NO996205L publication Critical patent/NO996205L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO996205A 1997-06-25 1999-12-15 Behandling av insulinresistens med veksthormonutskillelsesmiddel NO996205L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO996205D0 true NO996205D0 (no) 1999-12-15
NO996205L NO996205L (no) 1999-12-15

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996205A NO996205L (no) 1997-06-25 1999-12-15 Behandling av insulinresistens med veksthormonutskillelsesmiddel

Country Status (41)

Country Link
US (3) US6448263B1 (no)
EP (1) EP1000085B1 (no)
JP (2) JP2000514099A (no)
KR (1) KR20010014224A (no)
CN (2) CN1530107A (no)
AP (1) AP1145A (no)
AR (1) AR012256A1 (no)
AT (1) ATE305477T1 (no)
AU (1) AU747510B2 (no)
BG (1) BG104008A (no)
BR (1) BR9810477A (no)
CA (1) CA2294464A1 (no)
CO (1) CO4950621A1 (no)
DE (1) DE69831745T2 (no)
DZ (1) DZ2539A1 (no)
EA (1) EA002089B1 (no)
EG (1) EG21712A (no)
ES (1) ES2248899T3 (no)
HK (1) HK1028051A1 (no)
HN (1) HN1998000088A (no)
HR (1) HRP980361A2 (no)
HU (1) HUP0001922A3 (no)
ID (1) ID24345A (no)
IL (7) IL154114A0 (no)
IN (1) IN189724B (no)
IS (1) IS5275A (no)
MA (1) MA24581A1 (no)
NO (1) NO996205L (no)
NZ (1) NZ500655A (no)
OA (1) OA11242A (no)
PA (1) PA8452601A1 (no)
PE (1) PE105399A1 (no)
PL (1) PL337659A1 (no)
SK (1) SK175699A3 (no)
TN (1) TNSN98113A1 (no)
TR (1) TR199903257T2 (no)
TW (1) TW553943B (no)
UA (1) UA64751C2 (no)
WO (1) WO1998058949A1 (no)
YU (1) YU70199A (no)
ZA (1) ZA985546B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
KR20050071498A (ko) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
PL1828480T3 (pl) * 2004-12-21 2014-10-31 Solenis Tech Cayman Lp Reaktywne żywice kationowe do zastosowania jako czynniki wzmacniające na sucho i na mokro w układach wytwarzania papieru zawierających jony siarczynowe
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US20130296358A1 (en) 2012-05-03 2013-11-07 Ameet Vijay Ambarkhane 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2910123C (en) * 2013-05-28 2021-11-02 Raqualia Pharma Inc. Polymorph form of 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro­pyrazolo[4,3-c]pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide l-tartrate
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CA2951619C (en) * 2014-08-05 2023-01-10 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
CN106795158A (zh) * 2014-10-31 2017-05-31 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的四氢吡唑并吡啶衍生物
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
EP0669830A4 (en) 1992-11-06 1997-02-26 Merck & Co Inc SUBSTITUTED DIPEPTIDE ANALOGS PROMOTING THE RELEASE OF GROWTH HORMONE.
NZ258412A (en) 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
CN1211991A (zh) 1995-12-22 1999-03-24 诺沃挪第克公司 具有生长激素释放性质的化合物
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
EP1001970B1 (en) * 1997-06-25 2007-03-07 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
JP2005097261A (ja) 2005-04-14
IS5275A (is) 1999-11-26
DE69831745D1 (de) 2006-02-09
CN1152049C (zh) 2004-06-02
TNSN98113A1 (fr) 2005-03-15
DE69831745T2 (de) 2006-08-31
WO1998058949A1 (en) 1998-12-30
AR012256A1 (es) 2000-09-27
ATE305477T1 (de) 2005-10-15
CN1530107A (zh) 2004-09-22
EA002089B1 (ru) 2001-12-24
UA64751C2 (uk) 2004-03-15
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
AU7445698A (en) 1999-01-04
EP1000085A1 (en) 2000-05-17
AP9801267A0 (en) 1998-06-30
JP2000514099A (ja) 2000-10-24
NO996205L (no) 1999-12-15
CN1259140A (zh) 2000-07-05
IL133626A0 (en) 2001-04-30
US6630487B2 (en) 2003-10-07
IL156465A0 (en) 2004-01-04
KR20010014224A (ko) 2001-02-26
AU747510B2 (en) 2002-05-16
IL156465A (en) 2004-07-25
TR199903257T2 (xx) 2000-12-21
CO4950621A1 (es) 2000-09-01
NZ500655A (en) 2002-02-01
EP1000085B1 (en) 2005-09-28
PL337659A1 (en) 2000-08-28
EG21712A (en) 2002-02-27
ZA985546B (en) 2000-01-10
ID24345A (id) 2000-07-13
IL154115A0 (en) 2003-07-31
US20030100561A1 (en) 2003-05-29
AP1145A (en) 2003-02-14
IL154111A0 (en) 2003-07-31
BR9810477A (pt) 2007-05-22
US6448263B1 (en) 2002-09-10
DZ2539A1 (fr) 2003-02-08
PE105399A1 (es) 1999-11-04
BG104008A (en) 2000-07-31
CA2294464A1 (en) 1998-12-30
SK175699A3 (en) 2001-04-09
EA199901075A1 (ru) 2000-08-28
PA8452601A1 (es) 2000-05-24
JP3742643B2 (ja) 2006-02-08
HRP980361A2 (en) 1999-02-28
US6867202B1 (en) 2005-03-15
YU70199A (sh) 2003-01-31
HN1998000088A (es) 1999-01-08
IN189724B (no) 2003-04-19
TW553943B (en) 2003-09-21
HUP0001922A3 (en) 2001-02-28
ES2248899T3 (es) 2006-03-16
OA11242A (en) 2003-07-23
IL154116A0 (en) 2003-07-31
IL154114A0 (en) 2003-07-31
MA24581A1 (fr) 1998-12-31
HK1028051A1 (en) 2001-02-02

Similar Documents

Publication Publication Date Title
NO996205L (no) Behandling av insulinresistens med veksthormonutskillelsesmiddel
FI963482A0 (fi) Menetelmä hematopoieesin stimuloimiseksi hemoglobiinilla
NO973446D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
DE69531573D1 (de) Implantierbare rohrförmige Prothese mit Manschetten
DE69837264D1 (de) Dipeptidderivate zur förderung der sekretion von wachstumshormon
DK0885961T3 (da) Hidtil ukendte insulinderivater med hurtig indtræden af virkning
EP0741578A4 (en) HUMAN GROWTH HORMONE
DE69835103D1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69731979D1 (de) Dialysekatheter mit starren und kollabierbaren lumina
NO20001242L (no) April - et nytt protein med veksteffekter
EE200100479A (et) Kasvuhormooni nõristitena kasulikud heterotsüklilised aromaatsed ühendid ja nende kasutamine
PL338883A1 (en) Growth hormone secretion stimulating compounds
NO991186L (no) Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
NO975992L (no) Forbindelser med veksthormonfrigjörende egenskaper
DE69309698D1 (de) Hautbehandlung mit adhäsionsverstärkenden eigenschaften
PL329851A1 (en) Treatment of diseases associated with vegf
DK0907358T3 (da) Behandling med ensartet afgivelse af lægemiddel
ZA987383B (en) Treatment of congestive heart failure with growth hormone secretagogues.
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
NO996265D0 (no) Behandling av diabetes med rosiglitazon og insulin
AU7609298A (en) Treatment of heart failure with growth hormone
HK1042253A1 (zh) 化合物及其用於治療糖尿病並發症的用途
SI1007085T1 (en) Use of growth hormone in compositions for treating insulin resistance in the heart
SE9200678D0 (sv) Use of human growth hormone

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application